- Home
- NTSK vs EXAS Comparison
NTSK vs EXAS Comparison
Compare NTSK & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTSK
- EXAS
- Stock Information
- Founded
- NTSK 2012
- EXAS 1995
- Country
- NTSK United States
- EXAS United States
- Employees
- NTSK N/A
- EXAS N/A
- Industry
- NTSK Computer Software: Prepackaged Software
- EXAS Medical Specialities
- Sector
- NTSK Technology
- EXAS Health Care
- Exchange
- NTSK Nasdaq
- EXAS Nasdaq
- Market Cap
- NTSK 9.3B
- EXAS 10.6B
- IPO Year
- NTSK 2025
- EXAS N/A
- Fundamental
- Price
- NTSK $22.66
- EXAS $57.16
- Analyst Decision
- NTSK
- EXAS Strong Buy
- Analyst Count
- NTSK 0
- EXAS 21
- Target Price
- NTSK N/A
- EXAS $67.86
- AVG Volume (30 Days)
- NTSK 7.4M
- EXAS 2.3M
- Earning Date
- NTSK 01-01-0001
- EXAS 11-04-2025
- Dividend Yield
- NTSK N/A
- EXAS N/A
- EPS Growth
- NTSK N/A
- EXAS N/A
- EPS
- NTSK N/A
- EXAS N/A
- Revenue
- NTSK $615,512,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- NTSK N/A
- EXAS $16.68
- Revenue Next Year
- NTSK N/A
- EXAS $12.08
- P/E Ratio
- NTSK N/A
- EXAS N/A
- Revenue Growth
- NTSK 32.29
- EXAS 12.55
- 52 Week Low
- NTSK $21.02
- EXAS $38.81
- 52 Week High
- NTSK $27.99
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- NTSK N/A
- EXAS 68.72
- Support Level
- NTSK N/A
- EXAS $52.85
- Resistance Level
- NTSK N/A
- EXAS $54.74
- Average True Range (ATR)
- NTSK 0.00
- EXAS 1.40
- MACD
- NTSK 0.00
- EXAS 0.18
- Stochastic Oscillator
- NTSK 0.00
- EXAS 94.57
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.